SCHEMBL13846404

SCHEMBL13846404

C/C(=C/C(=O)c1ccccc1)Nc1ccccc1Oc1ccc2ccccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.59
▸ RAB9A P51151 7/20 0.59
▸ NPC1 O15118 6/20 0.59
▸ MAPK1 P28482 4/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ PYGM P11217 4/20 0.48
▸ TP53 P04637 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ GAA P10253 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ HPGD P15428 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13846397 0.87 MAPT (0.60) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846410 0.85 RAB9A (0.68) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13849752 0.85 MAPT (0.61) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL15504786 0.85 MAPT (0.58) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846403 0.84 MAPT (0.58) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13849747 0.84 MAPT (0.57) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846402 0.82 MAPT (0.55) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846411 0.79 MAPT (0.74) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846398 0.78 MAPT (0.52) MAPTRAB9ANPC1MAPK1SMN1; SMN2
SCHEMBL13846399 0.77 MAPT (0.51) MAPTRAB9ANPC1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2039677-B1 Organic compounds containing heteroatoms and their use in ziegler-natta catalyst with single activation center SHANGHAI INST ORGANIC CHEM (CN) 2014-04-23 — — EP disclosed
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2014-03-13 — — US disclosed
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2014-03-13 — — US disclosed
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2009-05-28 — — US disclosed
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2009-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST CCNT1, SP1, CCNT2 MAPT 450/4885RAB9A 4804/4885NPC1 1139/4885
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST CCNT1, SP1, CCNT2 MAPT 450/4885RAB9A 4804/4885NPC1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback